Amylin’s Woes Mount, Thanks to FDA Actions


By: dhtest

The stock of Byetta manufacturer Amylin Pharmaceuticals has lost more than half of its value over the past eight weeks, thanks to FDA concerns that the type 2 treatment may be connected with the deaths from acute pancreatitis of six Byetta users. Although the FDA has not proven a direct association between fatal pancreatitis and the use of Byetta, Amylin’s stock has fallen nevertheless.

Adding to the company’s problems is speculation among financial analysts that the FDA may delay until 2011 its approval of a long-acting form of Byetta called exenatide LAR. Amylin had hoped to receive approval by 2010 by the latest.

The long-acting form, which is administered by injection once a week, is now undergoing testing under FDA auspices. Current Byetta users inject the drug twice daily, usually before the morning and evening meals.

Third-quarter sales for Byetta are expected to reach $175 million, about $6 million to $7 million less than Wall Street forecasters had predicted earlier this year.

Byetta, which controls appetite and glucose production and stimulates beta cell growth, has been on the market since 2005. It is used by approximately 800,000 people with type 2 diabetes.  



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.